Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
Investing.com -- CytomX Therapeutics, Inc. (NASDAQ:CTMX) stock surged 120% after the company reported positive interim data from its Phase 1 dose escalation study of CX-2051 in patients with advanced colorectal cancer (CRC). The data, revealed on May 12, 2025, indicated a 28% confirmed response rate among patients treated with higher doses of the drug.
The South San Francisco-based biopharmaceutical company announced that the encouraging results were observed in unselected patients across doses prioritized for expansion. Notably, 3 of 7 evaluable patients treated with the upper expansion dose of 10 mg/kg every three weeks showed confirmed responses. Furthermore, the median progression-free survival reached 5.8 months as of the April 7th, 2025 data cutoff, with a favorable safety profile and no dose-limiting toxicities reported.
CytomX’s CEO Sean McCarthy expressed optimism about the drug’s potential, stating, "We believe we have broken important new ground with our data announced today, which show potential for markedly improved outcomes for CRC patients." McCarthy emphasized that CX-2051 has demonstrated durable anti-tumor activity in a challenging treatment landscape for late-line metastatic CRC and has been generally well-tolerated.
CX-2051 is a PROBODY® therapeutic, part of a new class of masked, conditionally activated biologics developed by CytomX. The company is planning to initiate a Phase 2 study in the first half of 2026, with additional Phase 1 data updates expected by the first quarter of 2026.
Investors responded positively to the news, which also included plans for potential combination studies in earlier lines of CRC and the evaluation of CX-2051 for other cancer types where EpCAM is expressed.
The stock movement reflects significant investor optimism surrounding CytomX’s progress and the potential impact of its innovative treatments on the oncology market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.